A high blood level in the venous chamber and a wet-stored dialyzer help to reduce exposure for microemboli during hemodialysis

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Ulf Forsberg ◽  
Per Jonsson ◽  
Christofer Stegmayr ◽  
Fredrik Jonsson ◽  
Bo Nilsson ◽  
...  
Keyword(s):  
Blood Level ◽  
High Blood Level

A High Blood Level in the Air Trap Reduces Microemboli During Hemodialysis

2012 ◽  
Vol 36 (6) ◽  
pp. 525-529 ◽  
Author(s):  
Ulf Forsberg ◽  
Per Jonsson ◽  
Christofer Stegmayr ◽  
Bernd Stegmayr
Keyword(s):  
Blood Level ◽  
High Blood Level

scholarly journals Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6
Author(s):  
F. Jacques ◽  
I. Gaboury ◽  
S. Christie ◽  
F. Grand'Maison
Keyword(s):  
Multiple Sclerosis ◽  
Combination Therapy ◽  
Blood Level ◽  
Interferon Beta ◽  
Lymphocyte Activation ◽  
Therapeutic Benefit ◽  
Open Label ◽  
High Blood Level ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients

Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive therapeutic benefit through the complementary mechanisms of action of these two therapeutics. In this randomized, open-label, multicenter, two-arm pilot study, the authors examined the safety and tolerability of the combination of interferon beta-1b and tacrolimus in relapsing remitting (RRMS) and secondary progressive (SPMS) multiple sclerosis patients who have failed one or more immunomodulatory therapies. Patients (n=25) received a combination of interferon beta-1b subcutaneously every other day and oral tacrolimus (low blood level tacrolimus, 1–5 ng/mL, or high blood level tacrolimus, 5–10 ng/mL) for a period of 38 weeks. The combination therapy of interferon beta-1b and tacrolimus over the 10-month period of the study was shown to be safe and relatively well tolerated. There were no unexpected adverse events occurring as the result of the combination therapy. Further study of this combination therapy in patients with multiple sclerosis unresponsive to conventional therapy is warranted.

scholarly journals Blood Level Omega-3 Fatty Acids as Risk Determinant Molecular Biomarker for Prostate Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-15 ◽  
Author(s):  
Mishell Kris Sorongon-Legaspi ◽  
Michael Chua ◽  
Maria Christina Sio ◽  
Marcelino Morales
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Blood Level ◽  
Prostate Cancer Risk ◽  
Positive Association ◽  
Case Control ◽  
Blood Levels ◽  
High Grade ◽  
Omega 3 ◽  
High Blood Level

Previous researches involving dietary methods have shown conflicting findings. Authors sought to assess the association of prostate cancer risk with blood levels of omega-3 polyunsaturated fatty acids (n-3 PUFA) through a meta-analysis of human epidemiological studies in available online databases (July, 2012). After critical appraisal by two independent reviewers, Newcastle-Ottawa Quality Assessment Scale (NOQAS) was used to grade the studies. Six case control and six nested case control studies were included. Results showed nonsignificant association of overall effect estimates with total or advanced prostate cancer or high-grade tumor. High blood level of alpha-linolenic acid (ALA) had nonsignificant positive association with total prostate cancer risk. High blood level of docosapentaenoic acid (DPA) had significant negative association with total prostate cancer risk. Specific n-3 PUFA in fish oil, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) had positive association with high-grade prostate tumor risk only after adjustment of interstudy variability. There is evidence that high blood level of DPA that is linked with reduced total prostate cancer risk and elevated blood levels of fish oils, EPA, and DHA is associated with high-grade prostate tumor, but careful interpretation is needed due to intricate details involved in prostate carcinogenesis and N-3 PUFA metabolism.

Prehospital Treatment of Patients with IV Heroin Overdose: What Are We Treating?

1997 ◽  
Vol 12 (2) ◽  
pp. 92-95 ◽  
Author(s):  
Carsten Boe Pedersen ◽  
Anni Steentoft ◽  
Karen Worm ◽  
Michael Sprehn ◽  
Torben Mogensen ◽  
...  
Keyword(s):  
Blood Level ◽  
Blood Sampling ◽  
Blood Levels ◽  
Multiple Drug ◽  
Prehospital Treatment ◽  
High Blood Level ◽  
Heroin Overdose ◽  
Heroin Abuse ◽  
Minor Tranquilizers

AbstractObjective:To measure blood levels of morphine and additional drugs in patients suspected of intravenous (IV) heroin abuse and to evaluate the effects of antidote treatment.Design:Prehospital blood sampling in 52 patients.Results:Forty-five patients were blood-positive for heroin, eight of whom were hospitalized. Forty-one patients also had abused additional drugs: minor tranquilizers, ethanol, amphetamine, cocaine, and/or carbamazepine. Seven patients had taken either only methadone or ketobemidione: one was admitted. Treatment with increasing doses of naloxone indicated a necessity for hospitalization. Six of 14 patients treated with naloxone (1.8 mg were hospitalized. Seven patients had an extremely high blood level of morphine (0.2 mg/kg), that could be reverted with naloxone in moderate doses.Conclusion:This study indicates that under prehospital conditions, it is difficult to identify a patient intoxicated only with intravenous heroin. Nearly all patients treated were cases of multiple drug/alcohol overdoses. Even the symptoms associated with extremely high blood levels of morphine could be reversed with naloxone in moderate doses.

scholarly journals Intracerebral haemorrhage with a fluid–blood level

2021 ◽  
Vol 14 (8) ◽  
pp. e244486
Author(s):  
Diogo Mendes Pedro ◽  
Carlos Carrilho Anjo ◽  
Teresa Fonseca ◽  
António Pais de Lacerda
Keyword(s):  
Blood Level ◽  
Intracerebral Haemorrhage ◽  
Fluid Blood
Sign in / Sign up

Export Citation Format

Share Document